AQUA07 / Chugai Pharmaceutical, Roche - LARVOL DELTA

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=102 | Recruiting | Sponsor: Chugai Pharmaceutical | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK

2026: Key R&D milestones (Chugai Press Release) - "AQUA07 is the third clinical-stage project leveraging SnipeTide, our proprietary macrocyclic peptide drug discovery platform. We have just received confirmation that the first patient was dosed earlier today in a clinical trial for ALK-positive non-small cell lung cancer....AQUA07 was granted Fast Track designation by the U.S. FDA in May 2026."

Fast track • Trial status • Non Small Cell Lung Cancer